Text this: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

 _    _     ______               ___     _    _   
| |  | ||  /_   _//     ___     / _ \\  | |  | || 
| |/\| ||   -| ||-     /   ||  | / \ || | |/\| || 
|  /\  ||   _| ||_    | [] ||  | \_/ || |  /\  || 
|_// \_||  /_____//    \__ ||   \___//  |_// \_|| 
`-`   `-`  `-----`      -|_||   `---`   `-`   `-` 
                         `-`